Rate of malignancy for thyroid nodules with AUS/FLUS cytopathology in a tertiary care center – a retrospective cohort study

Abstract Background Thyroid nodules are stratified through fine-needle aspiration (FNA) and are often categorized using The Bethesda System for Reporting Thyroid Cytopathology, which estimates the risk of malignancy for six cytopathological categories. The atypia of undetermined significance (AUS) a...

Full description

Bibliographic Details
Main Authors: Kalpesh Hathi, Tarek Rahmeh, Vicki Munro, Victoria Northrup, Ali Sherazi, Christopher J. Chin
Format: Article
Language:English
Published: BMC 2021-10-01
Series:Journal of Otolaryngology - Head and Neck Surgery
Subjects:
Online Access:https://doi.org/10.1186/s40463-021-00530-0
_version_ 1797970419322454016
author Kalpesh Hathi
Tarek Rahmeh
Vicki Munro
Victoria Northrup
Ali Sherazi
Christopher J. Chin
author_facet Kalpesh Hathi
Tarek Rahmeh
Vicki Munro
Victoria Northrup
Ali Sherazi
Christopher J. Chin
author_sort Kalpesh Hathi
collection DOAJ
description Abstract Background Thyroid nodules are stratified through fine-needle aspiration (FNA) and are often categorized using The Bethesda System for Reporting Thyroid Cytopathology, which estimates the risk of malignancy for six cytopathological categories. The atypia of undetermined significance (AUS) and follicular lesion of undetermined significance (FLUS) categories have varying malignancy rates reported in the literature which can range from 6 to 72.9%. Due to this heterogeneity, we assessed the malignancy rate and effectiveness of repeat FNA (rFNA) for AUS/FLUS thyroid cytopathology at our institution. Methods Electronic health records of patients with AUS/FLUS thyroid cytopathology on FNA at our center since the implementation of the Bethesda System on May 1, 2014–December 31, 2019 were retrospectively reviewed. Patient demographics, treatment pathway, and pathology results were collected. The treatment pathway of the nodules, the rFNA results, and the malignant histopathology results were reported. Malignancy rates were calculated as an upper and lower limit estimate. Results This study described 182 AUS/FLUS thyroid nodules from 177 patients. In total, 24 thyroid nodules were deemed malignant upon histopathology, yielding a final malignancy rate of 13.2–25.3%. All of the malignancies were variants of papillary thyroid carcinoma. The malignancy rate of the nodules which underwent resection without rFNA (21.5%) was lower than the malignancy rate of the nodules which underwent resection after rFNA (43.8%). 45.5% of the rFNA results were re-classified into more definitive categories. Conclusion The malignancy rate of AUS/FLUS thyroid cytopathology at our center is in line with the risk of malignancy stated by the 2017 Bethesda System. However, our malignancy rate is lower than some other Canadian centers and approximately half of our rFNAs were re-classified, highlighting the importance of establishing center-specific malignancy and rFNA re-classification rates to guide treatment decisions.
first_indexed 2024-04-11T03:17:34Z
format Article
id doaj.art-cfedc85888ef45e5867309abfac80cd5
institution Directory Open Access Journal
issn 1916-0216
language English
last_indexed 2024-04-11T03:17:34Z
publishDate 2021-10-01
publisher BMC
record_format Article
series Journal of Otolaryngology - Head and Neck Surgery
spelling doaj.art-cfedc85888ef45e5867309abfac80cd52023-01-02T10:12:56ZengBMCJournal of Otolaryngology - Head and Neck Surgery1916-02162021-10-015011710.1186/s40463-021-00530-0Rate of malignancy for thyroid nodules with AUS/FLUS cytopathology in a tertiary care center – a retrospective cohort studyKalpesh Hathi0Tarek Rahmeh1Vicki Munro2Victoria Northrup3Ali Sherazi4Christopher J. Chin5Dalhousie Medicine New BrunswickDepartment of Laboratory Medicine, Horizon Health Network, Saint John Regional HospitalDalhousie Medicine New BrunswickDalhousie Medicine New BrunswickDepartment of Laboratory Medicine, Horizon Health Network, Saint John Regional HospitalDalhousie Medicine New BrunswickAbstract Background Thyroid nodules are stratified through fine-needle aspiration (FNA) and are often categorized using The Bethesda System for Reporting Thyroid Cytopathology, which estimates the risk of malignancy for six cytopathological categories. The atypia of undetermined significance (AUS) and follicular lesion of undetermined significance (FLUS) categories have varying malignancy rates reported in the literature which can range from 6 to 72.9%. Due to this heterogeneity, we assessed the malignancy rate and effectiveness of repeat FNA (rFNA) for AUS/FLUS thyroid cytopathology at our institution. Methods Electronic health records of patients with AUS/FLUS thyroid cytopathology on FNA at our center since the implementation of the Bethesda System on May 1, 2014–December 31, 2019 were retrospectively reviewed. Patient demographics, treatment pathway, and pathology results were collected. The treatment pathway of the nodules, the rFNA results, and the malignant histopathology results were reported. Malignancy rates were calculated as an upper and lower limit estimate. Results This study described 182 AUS/FLUS thyroid nodules from 177 patients. In total, 24 thyroid nodules were deemed malignant upon histopathology, yielding a final malignancy rate of 13.2–25.3%. All of the malignancies were variants of papillary thyroid carcinoma. The malignancy rate of the nodules which underwent resection without rFNA (21.5%) was lower than the malignancy rate of the nodules which underwent resection after rFNA (43.8%). 45.5% of the rFNA results were re-classified into more definitive categories. Conclusion The malignancy rate of AUS/FLUS thyroid cytopathology at our center is in line with the risk of malignancy stated by the 2017 Bethesda System. However, our malignancy rate is lower than some other Canadian centers and approximately half of our rFNAs were re-classified, highlighting the importance of establishing center-specific malignancy and rFNA re-classification rates to guide treatment decisions.https://doi.org/10.1186/s40463-021-00530-0ThyroidBethesdaAUS/FLUSNoduleCytopathologyFNA
spellingShingle Kalpesh Hathi
Tarek Rahmeh
Vicki Munro
Victoria Northrup
Ali Sherazi
Christopher J. Chin
Rate of malignancy for thyroid nodules with AUS/FLUS cytopathology in a tertiary care center – a retrospective cohort study
Journal of Otolaryngology - Head and Neck Surgery
Thyroid
Bethesda
AUS/FLUS
Nodule
Cytopathology
FNA
title Rate of malignancy for thyroid nodules with AUS/FLUS cytopathology in a tertiary care center – a retrospective cohort study
title_full Rate of malignancy for thyroid nodules with AUS/FLUS cytopathology in a tertiary care center – a retrospective cohort study
title_fullStr Rate of malignancy for thyroid nodules with AUS/FLUS cytopathology in a tertiary care center – a retrospective cohort study
title_full_unstemmed Rate of malignancy for thyroid nodules with AUS/FLUS cytopathology in a tertiary care center – a retrospective cohort study
title_short Rate of malignancy for thyroid nodules with AUS/FLUS cytopathology in a tertiary care center – a retrospective cohort study
title_sort rate of malignancy for thyroid nodules with aus flus cytopathology in a tertiary care center a retrospective cohort study
topic Thyroid
Bethesda
AUS/FLUS
Nodule
Cytopathology
FNA
url https://doi.org/10.1186/s40463-021-00530-0
work_keys_str_mv AT kalpeshhathi rateofmalignancyforthyroidnoduleswithausfluscytopathologyinatertiarycarecenteraretrospectivecohortstudy
AT tarekrahmeh rateofmalignancyforthyroidnoduleswithausfluscytopathologyinatertiarycarecenteraretrospectivecohortstudy
AT vickimunro rateofmalignancyforthyroidnoduleswithausfluscytopathologyinatertiarycarecenteraretrospectivecohortstudy
AT victorianorthrup rateofmalignancyforthyroidnoduleswithausfluscytopathologyinatertiarycarecenteraretrospectivecohortstudy
AT alisherazi rateofmalignancyforthyroidnoduleswithausfluscytopathologyinatertiarycarecenteraretrospectivecohortstudy
AT christopherjchin rateofmalignancyforthyroidnoduleswithausfluscytopathologyinatertiarycarecenteraretrospectivecohortstudy